Intriguingly, the properties of ebselen, such as reducing iron entry by inhibiting DMT-1 and increasing FPN1 expression, and antioxidant characteristics by mimicking the function of GPx, make it an exciting and promising possibility for adjuvant therapy in patients with thalassemia alongside the standard treatment with iron chelators, particularly in severe cases with cardiomyopathy. This evidence concerns the gene SLC11A2 and thalassemia.